PMID- 37913914
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 264
DP  - 2023 Dec
TI  - The SMAC mimetic birinapant alleviates lipopolysaccharide-induced acute lung 
      injury by inhibiting MAPK signaling.
PG  - 31-35
LID - S0165-2478(23)00180-3 [pii]
LID - 10.1016/j.imlet.2023.10.008 [doi]
AB  - The second mitochondria-derived activator of caspases (SMAC) mimetic birinapant 
      attenuated liver injury by inhibited the degradation of tumor necrosis factor 
      receptor-associated factor 3 (TRAF3) and activation of mitogen-activated protein 
      kinase (MAPK) signaling pathway in liver macrophage, but its role in LPS induced 
      acute lung injury (ALI) is not understood. The present study was to investigate 
      the effects of birinapant on ALI and its possible mechanism. A dose of birinapant 
      (30 mg/kg) or a vehicle was administered intravenously 24 hours before LPS (100 
      mug) stimulation in mice. The levels of TNF-alpha, IL-6 and IL-1beta in bronchoalveolar 
      lavage fluid (BALF) were measured by ELISA. The infiltrated macrophages and 
      expression of monocyte chemoattractant protein-1 (MCP-1) was determined by 
      immunohistochemistry staining in the lung tissues. The JNK and p38 MAPK 
      activation, protein expression and K48-linked polyubiquitination of TRAF3 were 
      determined in alveolar macrophage cell line (MH-S cells) after 1mug/ml LPS 
      stimulation. The results showed that the birinapant down-regulated the levels of 
      TNF-alpha, IL-6 and IL-1beta in the BALF. In addition, birinapant markedly inhibited 
      macrophages infiltration and MCP-1 protein expression in lung tissues. At last, 
      birinapant suppressed the MAPKsignaling pathway and K48-linked ubiquitinated 
      degradation of TRAF3 in MH-S cells after LPS administration. In conclusion, the 
      results proved that birinapant protected against LPS-induced ALI through 
      inhibiting MAPK activation and K48-linked ubiquitination of TRAF3 in alveolar 
      macrophages.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Hu, Hui
AU  - Hu H
AD  - Department of Traumatology, Chongqing University Central Hospital, Chongqing 
      Emergency Medical Center, No.1 Jiankang Road, Yuzhong District, Chongqing, China.
FAU - Ma, Man
AU  - Ma M
AD  - Department of Traumatology, Chongqing University Central Hospital, Chongqing 
      Emergency Medical Center, No.1 Jiankang Road, Yuzhong District, Chongqing, China.
FAU - Li, Tao
AU  - Li T
AD  - Department of Traumatology, Chongqing University Central Hospital, Chongqing 
      Emergency Medical Center, No.1 Jiankang Road, Yuzhong District, Chongqing, China.
FAU - Shi, Li
AU  - Shi L
AD  - Department of Traumatology, Chongqing University Central Hospital, Chongqing 
      Emergency Medical Center, No.1 Jiankang Road, Yuzhong District, Chongqing, China.
FAU - Li, Peizhi
AU  - Li P
AD  - Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing 400016, China. Electronic address: 
      lipeizhi@cqmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231031
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - 0 (Lipopolysaccharides)
RN  - 6O4Z07B57R (birinapant)
RN  - 0 (TNF Receptor-Associated Factor 3)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.22.- (Caspases)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-1beta)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Mitogen-Activated Protein Kinases/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - TNF Receptor-Associated Factor 3/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Caspases/adverse effects/metabolism
MH  - Interleukin-6/metabolism
MH  - Signal Transduction
MH  - *Acute Lung Injury/chemically induced/drug therapy
MH  - Lung/pathology
MH  - Interleukin-1beta/metabolism
MH  - Mitochondria/metabolism
OTO - NOTNLM
OT  - Acute lung injury
OT  - Birinapant
OT  - Lipopolysaccharide
OT  - Macrophage
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/11/02 00:42
MHDA- 2023/12/17 09:44
CRDT- 2023/11/01 20:28
PHST- 2023/05/17 00:00 [received]
PHST- 2023/10/19 00:00 [revised]
PHST- 2023/10/28 00:00 [accepted]
PHST- 2023/12/17 09:44 [medline]
PHST- 2023/11/02 00:42 [pubmed]
PHST- 2023/11/01 20:28 [entrez]
AID - S0165-2478(23)00180-3 [pii]
AID - 10.1016/j.imlet.2023.10.008 [doi]
PST - ppublish
SO  - Immunol Lett. 2023 Dec;264:31-35. doi: 10.1016/j.imlet.2023.10.008. Epub 2023 Oct 
      31.